Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) stated this week that that the protocol for a planned physician initiated Phase 2 clinical study of NP-120 (Ifenprodil) for COVID-19 coronavirus-infected patients in South Korea has been finalized.
For more on this news,
click here.
The clinical stage pharmaceutical development Company recently submitted its planned Phase 2 study of its re-purposed drug
Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough for ethics approval in Australia. Ethics approval can take four to eight weeks.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.